[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].

Authors

Sophie Park, Lionel Adès, Olivier Kosmider, Orianne Wagner-Ballon, Valérie Bardet, Emmanuel Gyan, Nicolas Chapuis, Jean-Baptiste Micol, Jacqueline Dubow, Evelyne Chartier, Aline Renneville, Lin-Pierre Zhao, Audrey Bidet, Sophie Dimicoli-Salazar, Marie Sébert, Lise Larcher, Lucie Freiman, Mathieu Meunier, Thibault Comont, José-Miguel Torregrosa-Diaz, Sophie Dennetière, Odile Rauzy, Juliette Pénichoux, Thomas Cluzeau, Pierre Peterlin, Maël Heiblig, Christophe Willekens, Alice Garnier, Raphaël Itzykson, Arsène Mekinian, Marie Robin, Maud D'Aveni-Piney, Marie-Anne Hospital, Fatiha Chermat, Michaela Fontenay, Pierre Fenaux

Published in

Bulletin du cancer. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

This document presents the national recommendations of the Francophone Group for Myelodysplastic Syndromes (Groupe Francophone des Myélodysplasies, GFM) for the diagnosis and management of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and VEXAS syndrome. Diagnosis relies on the integration of complete blood count data, bone marrow morphology, cytogenetics, and molecular biology, including targeted gene sequencing panels. The document also provides surveillance recommendations for clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenias of undetermined significance (CCUS), which carry a risk of progression to MDS of up to 10-30% over ten years. Prognostic stratification is based on the IPSS-R and IPSS-M scoring systems, the latter incorporating somatic mutations to refine risk assessment. For lower-risk MDS, management primarily targets anemia through erythropoiesis-stimulating agents, luspatercept, and imetelstat (available very soon). Higher-risk forms are treated with azacitidine, potentially combined with venetoclax. Allogeneic hematopoietic stem cell transplantation continues to be refined at all stages, from donor selection to post-transplant management. Finally, the management of VEXAS syndrome is specifically detailed, encompassing corticosteroids, anti-inflammatory biotherapies, and azacitidine.

PMID:
42881104
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.